BioNetwork West 2015 (past event)
October 26 - 28, 2015
Contact Us: 1.888.482.6012
Innovative Dealmaking
08:00 - 08:45 Registration And Networking Breakfast
Registration sponsored by GE Capital Healthcare Financial Services.
08:45 - 08:50 Welcoming Remarks
08:50 - 09:00 Chairperson’s Opening Address
09:00 - 09:30 Therapeutic Focus Area Ice Breaker Roundtables
Speakers:
Ilan Zipkin Senior Investment Director Takeda Ventures, Inc.
Kia Motesharei Head, Global Licensing & Business Development, Immunology EMD Serono / Merck KGaA
Joshua Grass Senior Vice President of Corporate and Business Development BioMarin Pharmaceutical Inc
John McDonald Vice President of Business Development Biogen
Michael Bayewitch Director, Search & Evaluation, Biologics Teva Pharmaceuticals
Michael Attar Executive Director, Business Development Celgene Corporation
Ilan Zipkin Senior Investment Director Takeda Ventures, Inc.
Kia Motesharei Head, Global Licensing & Business Development, Immunology EMD Serono / Merck KGaA
Joshua Grass Senior Vice President of Corporate and Business Development BioMarin Pharmaceutical Inc
John McDonald Vice President of Business Development Biogen
Michael Bayewitch Director, Search & Evaluation, Biologics Teva Pharmaceuticals
Michael Attar Executive Director, Business Development Celgene Corporation
Get to know others with similar interests as you. Choose the therapeutic area at the top of your partnership priorities. You'll sit with 10 - 20 others seeking similar opportunities to debate the advantages and challenges assocatied with your chosen area, and start making connections!
#1 Neurodegenerative Diseases
Ilan Zipkin, Senior Investment Director, Takeda Ventures
#2 Rare Disease
Joshua A. Grass, SVP, Business and Corporate Development, BioMarin Pharmaceutical
#3 Biosimilars Across Therapeutic Areas
Michael Bayewitch, Director, Search & Evaluation, Biologics, Teva Pharmaceuticals
#4 Immunology
Kia Motesharei, Head, Global Licensing & Business Development, Immunology, EMD Serono
#5 Gene Therapy
John McDonald, VP Business Development and Mergers & Acquisitions, Biogen
#6 Oncology
Michael Attar, Executive Director, Business Development, Celgene Corporation
#7 Other (Free Flow Table)
EMD Serono / Merck KGaA
BioMarin Pharmaceutical Inc
Celgene Corporation
#1 Neurodegenerative Diseases
Ilan Zipkin, Senior Investment Director, Takeda Ventures
#2 Rare Disease
Joshua A. Grass, SVP, Business and Corporate Development, BioMarin Pharmaceutical
#3 Biosimilars Across Therapeutic Areas
Michael Bayewitch, Director, Search & Evaluation, Biologics, Teva Pharmaceuticals
#4 Immunology
Kia Motesharei, Head, Global Licensing & Business Development, Immunology, EMD Serono
#5 Gene Therapy
John McDonald, VP Business Development and Mergers & Acquisitions, Biogen
#6 Oncology
Michael Attar, Executive Director, Business Development, Celgene Corporation
#7 Other (Free Flow Table)
Kia Motesharei
Head, Global Licensing & Business Development, ImmunologyEMD Serono / Merck KGaA
Joshua Grass
Senior Vice President of Corporate and Business DevelopmentBioMarin Pharmaceutical Inc
Michael Attar
Executive Director, Business DevelopmentCelgene Corporation
09:30 - 10:00 Keynote: Winning Partnerships: What It Takes To Build A World Class BD Capability
As more and more companies embrace partnering as the key means to fill their pipelines, winning the race to access the most innovative new molecules and therapies is only becoming more and more competitive. Relying on a world-class position in a therapeutic area is no longer enough – because in the partnering game second place isn’t good enough. Getting a partnership deal signed requires a best-in-class Business Development capability – but what does that mean, and how does an organization evaluate whether they have one? This presentation will review:
• What a BD capability that is built to win “looks like” – what do the best-in-class organizations do?
• What steps an organization might take to benchmark where it stands against the competition
• How an organization can identify gaps based on the above assessment and develop recommendations to fill them
• What a BD capability that is built to win “looks like” – what do the best-in-class organizations do?
• What steps an organization might take to benchmark where it stands against the competition
• How an organization can identify gaps based on the above assessment and develop recommendations to fill them
Program
10:00 - 10:40 PANEL: Exploring The Latest Innovative Deal Structures And The Evolution Of Traditional Licensing And M&A
Some of the greatest innovators in Big Pharma share insight into their latest cutting-edge deal structures - how they came to be and hiccups that had to be worked out along the way. Take part to arm yourself with strategies to be an even more effective partner in a rapidly evolving deal structure environment.
• Assessing the most recent high profile deals and what made them a success
• Innovative deals: what structure was used and why?
• How is the partnering landscape evolving and what can we expect in the near and long-term future?
• Assessing the most recent high profile deals and what made them a success
• Innovative deals: what structure was used and why?
• How is the partnering landscape evolving and what can we expect in the near and long-term future?
1:1 Partnering Meetings
10:00 - 10:40 BeginProgram
10:40 - 11:10 Networking And Refreshment Break1:1 Partnering Meetings
10:40 - 11:10 ContinuedProgram
11:10 - 11:50 PANEL: Enhancing The Deal And Minimizing Complications Through Improved Due Diligence And Insight Generation
• Identifying steps for effective due diligence from early stage asset valuation to the late stages of the deal
• Using external insights and experts to know as much as you can about an asset and its potential before the late stages of the deal
• How can you start the due diligence process earlier to strengthen the relationship and problem solve?
• Lining up the many moving pieces in tight timelines to build trust
• Success stories of effective due diligence across the entire business development and licensing spectrum
EMD Serono / Merck KGaA
• Using external insights and experts to know as much as you can about an asset and its potential before the late stages of the deal
• How can you start the due diligence process earlier to strengthen the relationship and problem solve?
• Lining up the many moving pieces in tight timelines to build trust
• Success stories of effective due diligence across the entire business development and licensing spectrum
Kia Motesharei
Head, Global Licensing & Business Development, ImmunologyEMD Serono / Merck KGaA
1:1 Partnering Meetings
11:10 - 11:50 ContinuedProgram
11:50 - 12:05 Biotech Spotlight: G1 Therapeutics
1:1 Partnering Meetings
11:50 - 12:05 ContinuedProgram
12:05 - 12:20 Biotech Spotlight: Milestone Pharmaceuticals
1:1 Partnering Meetings
12:05 - 12:20 ContinuedProgram
12:20 - 12:35 Biotech Spotlight: AADi, an NCI STTR-funded company
AADi, an NCI STTR-funded company was founded by Dr. Neil Desai in 2011 to develop a targeted mTOR therapeutic based on the highly successful ‘nab’ nanoparticle albumin bound technology originally developed by Dr. Desai at Abraxis Bioscience. AADi’s first product, ABI-009, albumin-bound sirolimus (nab-rapamycin), a highly active form of sirolimus with nanoparticles of 100 nm coated with albumin, is based on the same technology as Abraxane® (nab-paclitaxel, Abraxis Bioscience, acquired by Celgene Corp in 2010 for ~$3B, 2015 est sales ~$1B). ABI-009 has a superior clinical and pharmacological profile compared to any other mTOR inhibitor. A phase 1 trial in patients with solid tumors showed promising safety and evidence of activity. Unlike other mTOR inhibitors, ABI-009 is being developed in highly select populations with diseases driven by mTOR activation that represent sizeable market opportunities. AADi is investigating the use of ABI-009 in a number of solid tumors and will initiate a registration study in a rare sarcoma in 2015. Through a NIH Fast-Track STTR grant, ABI-009 is being investigated in phase 1/2 trials for BCG-refractory bladder cancer. AADi also plans to initiate clinical studies in treatment of advanced pulmonary hypertension as well for treatment of rare pediatric cancers. AADi is currently in the process of raising capital to fund these opportunities.
1:1 Partnering Meetings
12:20 - 12:35 Continued
1:1 Partnering Meetings
12:35 - 12:50 ContinuedProgram
12:50 - 13:05 Biotech Spotlight: AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, (ACRX, NASDEX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. We were founded to solve the problems of post-operative intravenous patient-controlled analgesia (IV PCA). Our lead product, Zalviso™ (sufentanil sublingual microtablet system), is designed to address IV PCA problems which can cause harm to patients following surgery such as the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. Grünenthal, our European partner for Zalviso received a positive opinion recommending approval for Zalviso in Europe. We have three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain currently in Phase 3 development.
AcelRx Pharmaceuticals
Meera Desai
Director of Alliance Management and Corporate DevelopmentAcelRx Pharmaceuticals
1:1 Partnering Meetings
12:50 - 13:05 Continued13:05 - 14:05 Networking Luncheon
Program
14:05 - 14:45 PANEL: Understanding The Evolving Structure And Needs Of Big Pharma And Biotechs To Find The Perfect Partner
With patent cliffs, outcomes-based healthcare, M&A activity, and a growing global partnering environment, Big Pharma's partnering needs are constantly shifting. Organizations are responding to these shifts by restructing their BD groups, their focus, and their needs. Biotechs are also shifting their research, partnering processes, and resources to account for the changing environment. This panel will ensure you know how to most effectively go after your next partnership.
• Exploring current organizational structures of big pharma
• Who do biotechs, academia and other partners need to talk to and when?
• The differences between pharma and big biotechs when establishing partnerships
• How major corporate M&As can impact big pharma’s ability to partner
• Effective partnering tools for working with big pharma and biotechs
• Exploring current organizational structures of big pharma
• Who do biotechs, academia and other partners need to talk to and when?
• The differences between pharma and big biotechs when establishing partnerships
• How major corporate M&As can impact big pharma’s ability to partner
• Effective partnering tools for working with big pharma and biotechs
1:1 Partnering Meetings
14:05 - 14:45 ContinuedProgram
14:45 - 15:25 PANEL: Success Strategies For Early Stage Collaboration And Funding
Funding opportunities and resources for early stage life science projects are aplenty if you know where to look and who to talk to. But once you've identified early-stage collaboration opportunities, you need to put strategies in place to ensure mutual benefit and long-term success. You can put yourself many steps ahead by learning from the successes (and mistakes) of others, as outlined in this panel.
• Exploring the depth of sources for early stage funding
• How are different incubator programs being carried out today?
• What is essential for successful early stage collaboration?
• How strategic early stage collaborations can benefit your organization
• Exploring the depth of sources for early stage funding
• How are different incubator programs being carried out today?
• What is essential for successful early stage collaboration?
• How strategic early stage collaborations can benefit your organization
1:1 Partnering Meetings
14:45 - 15:25 ContinuedProgram
15:25 - 15:55 Networking And Refreshment Break1:1 Partnering Meetings
15:25 - 15:55 ContinuedProgram
15:55 - 16:10 Biotech Spotlight: RedHill Biopharma
1:1 Partnering Meetings
15:55 - 16:10 ContinuedProgram
16:10 - 16:25 Biotech Spotlight: NanoSmart Pharmaceuticals
NanoSmart Pharmaceuticals, Inc. is a private pharmaceutical company developing novel treatments for cancer and other diseases. The Company has developed and patented a drug delivery platform using human-derived, anti-nuclear antibodies (ANA) capable of targeting many different kinds of solid tumors and inflammatory diseases. The drug delivery platform, which consists of lipid nanoparticles coated with ANA, can be used to encapsulate off-patent FDA-approved drugs to create safer and more effective treatments with extended patent life. The versatility of this platform allows NanoSmart to efficiently pursue a broad drug development pipeline through licensing and partnership opportunities. NanoSmart’s initial focus is on pediatric cancer indications, a patient population that has been traditionally underserved in drug development. The company has obtained orphan drug designation from the FDA for two novel ANA-conjugated nanoparticle drug formulations that are currently in the preclinical phase for the treatment of Ewing’s Sarcoma.
1:1 Partnering Meetings
16:10 - 16:25 Continued1:1 Partnering Meetings
16:25 - 16:30 NCI Introduction
1:1 Partnering Meetings
16:25 - 16:30 ContinuedProgram
16:30 - 16:45 Biotech Spotlight: Etubics Corporation
Etubics Corporation, an NCI SBIR-funded company, based in Seattle, WA., is the 3rd generation clinical stage bio-pharmaceutical company, which has developed a proprietary 3rd generation gene delivery platform technology consisting of a genetically engineered adenovirus vector delivery system and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Phase 1 and 2 clinical trials to date show that the Etubics Platform overcomes challenges associated with all other virus platforms including prior generation adenoviruses. The Company’s gene delivery platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of cancers, infectious diseases and other chronic illnesses associated with genetic abortions.
1:1 Partnering Meetings
16:30 - 16:45 ContinuedProgram
16:45 - 17:00 Biotech Spotlight: Novomedix, Inc.
NovoMedix, an NCI SBIR-funded company, is a drug discovery company focusing on the discovery and development of new drugs that target unique pathways to provide safer, more effective therapies for life threatening diseases. Our current pipeline contains drugs from three different classes. The lead compounds are novel, orally available, small molecule translation inhibitors that prevent the growth and invasion of cancer cells and also prevent the surrounding stroma from supporting tumor growth. The most advanced drug is undergoing preclinical toxicity and toxicology studies in support of an IND for triple negative breast cancer. We are also developing novel drugs that prevent fibrosis and have demonstrated in vivo efficacy in a mouse transaortic constriction (TAC) model of heart failure. These drugs have a good safety profile and we believe that they will be useful in a wide variety of fibrotic diseases.
1:1 Partnering Meetings
16:45 - 17:00 ContinuedProgram
17:00 - 17:40 PANEL: Comparing Risks And Opportunities Across The Leading Emerging Markets Growth Areas
Is emerging markets business right for your organization? Probably, but you'll be much better equipped with the best areas to target and opportunities to seek after you hear this expert panel's perspective on business development in emerging markets.
• Exploring market trends in emerging markets
• What are the differences and similarities around doing business in top emerging markets (especially China, Brazil, Russia, and South Africa)
• Protecting your intellectual property when working with different countries
• Minimizing other risks and maximizing opportunities in emerging markets
• Exploring market trends in emerging markets
• What are the differences and similarities around doing business in top emerging markets (especially China, Brazil, Russia, and South Africa)
• Protecting your intellectual property when working with different countries
• Minimizing other risks and maximizing opportunities in emerging markets
1:1 Partnering Meetings
17:00 - 17:40 Continued17:40 - 23:59 Sunset Cocktail Reception
After a full day of relevant meetings, you have some new deals on the horizon. Here you can also witness the extraordinary sunset view on the horizon that everyone's been talking about as you sip a cocktail, carry on beneficial conversations from the day, and continue to build lasting relationships.